Immunovant, Inc. $IMVT Shares Newly Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC bought a new stake in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 545,730 shares of the company’s stock, valued at approximately $18,435,000.

Several other hedge funds have also bought and sold shares of IMVT. The Manufacturers Life Insurance Company acquired a new position in Immunovant during the second quarter worth approximately $1,871,000. Renaissance Technologies LLC bought a new stake in Immunovant in the first quarter valued at approximately $4,782,000. GSA Capital Partners LLP bought a new stake in Immunovant in the second quarter valued at approximately $2,515,000. Man Group plc bought a new stake in Immunovant in the second quarter valued at approximately $5,399,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Immunovant in the second quarter valued at approximately $2,996,000. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research report on Tuesday, August 25th. HC Wainwright reissued a “buy” rating on shares of Immunovant in a report on Thursday, September 24th. UBS Group reissued a “buy” rating on shares of Immunovant in a report on Wednesday, September 23rd. JPMorgan Chase & Co. increased their price target on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Truist Financial raised their price target on Immunovant from $30.00 to $33.00 and gave the company a “hold” rating in a report on Tuesday, November 10th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunovant has an average rating of “Moderate Buy” and a consensus target price of $44.60.

Read Our Latest Research Report on IMVT

Insider Activity

In other news, CTO Jay S. Stout sold 2,595 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $28.94, for a total transaction of $75,099.30. Following the completion of the sale, the chief technology officer owned 198,937 shares in the company, valued at $5,757,236.78. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Van Tuyl sold 1,327 shares of the company’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $32.06, for a total value of $42,543.62. Following the completion of the transaction, the insider directly owned 175,218 shares in the company, valued at $5,617,489.08. The trade was a 0.75% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 27,430 shares of company stock valued at $895,852. Company insiders own 1.90% of the company’s stock.

Immunovant Stock Performance

Shares of IMVT stock opened at $34.18 on Monday. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of -13.35 and a beta of 0.95. The company has a 50-day simple moving average of $32.64 and a 200 day simple moving average of $32.33. Immunovant, Inc. has a 52 week low of $21.86 and a 52 week high of $45.42.

Immunovant (NASDAQ:IMVT – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.27. During the same quarter last year, the business posted ($0.73) earnings per share. Sell-side analysts forecast that Immunovant, Inc. will post -2.78 EPS for the current year.

Immunovant Profile

(Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.

Read More

Want to see what other hedge funds are holding IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunovant, Inc. (NASDAQ:IMVT – Free Report).

Institutional Ownership by Quarter for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.